Standard BioTools announced two major transactions: a deal to sell its mass cytometry business to Multiplex Bio and a separate settlement with Illumina. The sale provides a $5 million promissory note at 6% interest maturing in five years, plus up to $5 million in contingent consideration, and may i…
LAB (Standard BioTools Inc.) is set to announce its Q2'26 results on July 30, time not specified. The earnings are expected to be disclosed at 8:00 AM ET (12:00 PM UTC).For Q2'26, revenue estimate is 20.80 million USD with EPS (earnings per share) anticipated at (0.01) USD. Learn more details at LA…
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.The proposed transactions may contain terms that could limit superior competing offers.Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We…
